Analysts see $3B potential in Sanofi-Regeneron cholesterol drug alirocumab

09/26/2013 | Reuters

Sanofi and Regeneron Pharmaceuticals' late-stage cholesterol therapy candidate alirocumab has the potential to become a blockbuster with more than $3 billion in sales, analysts said. Alirocumab belongs to a class of drugs called PCSK9 inhibitors. Deutsche Bank analysts said peak annual sales of alirocumab could reach exceed $3 billion, and BioMedTracker, an independent research firm, predicted sales of $3.7 billion by 2023.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Director, Corporate Counsel
Regeneron
Tarrytown, NY